Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus
Vaccine·
- DOI
- 10.1016/j.vaccine.2008.03.060
- PMID
- 18471943
- PMCID
- PMC2582145
- OpenAlex
- W2046391048
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Chikungunya virus is an emerging arbovirus transmitted primarily by Aedes mosquitoes, causing illness characterized by fever, rash, arthralgia, and occasionally neurological manifestations or fatal hemorrhagic conditions. Recent epidemics and the potential involvement of Aedes albopictus have raised pandemic concerns, yet no specific treatment or vaccine is currently available.
Structured evidence summary
Research question
The study aimed to develop and evaluate novel consensus-based DNA vaccines targeting Chikungunya virus capsid and envelope proteins.
Study design
This was a preclinical vaccine development study using a DNA vaccine strategy with consensus sequences for CHIKV antigens, delivered via electroporation to C57BL/6 mice. Immunogenicity was assessed through cellular immune response analysis, epitope mapping, and antibody ELISAs.
Population and setting
The study was conducted in C57BL/6 mice using intramuscular injection with adaptive constant-current electroporation.
Main findings
The consensus-based DNA vaccine constructs for CHIKV capsid, E1, and E2 proteins induced both potent and broad cellular immunity as demonstrated by epitope mapping. High-titer antibodies capable of recognizing native antigen were also generated.
Public-health relevance
Chikungunya virus is an emerging arbovirus transmitted primarily by Aedes mosquitoes, causing illness characterized by fever, rash, arthralgia, and occasionally neurological manifestations or fatal hemorrhagic conditions. Recent epidemics and the potential involvement of Aedes albopictus have raised pandemic concerns, yet no specific treatment or vaccine is currently available.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. The preclinical nature of the study, specific details of immune response magnitudes, durability of responses, and progression toward human trials require the original paper for decision-grade interpretation.
GIDS interpretation
This article was discoverable through classifier links to Chikungunya disease, transmission dynamics, treatment, and vaccination topics. The abstract provides context on CHIKV epidemiology and vaccine development strategy but does not report human surveillance data or connect to an active disease signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.